標(biāo)題: Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz [打印本頁] 作者: Washington 時間: 2025-3-21 16:57
書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)
書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)學(xué)科排名
書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡(luò)公開度
書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次
書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次學(xué)科排名
書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用
書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用學(xué)科排名
書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋
書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋學(xué)科排名
作者: AWRY 時間: 2025-3-21 23:18
,La régression linéaire multiple,g germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos作者: amyloid 時間: 2025-3-22 01:46
Pierre-André Cornillon,Eric Matzner-L?bera second remission followed by allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the advent of targeted therapies such as monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR)-T cells, a better understanding of prognostic genomic markers, refined techniques for d作者: 極為憤怒 時間: 2025-3-22 08:37 作者: Virtues 時間: 2025-3-22 09:52 作者: GLARE 時間: 2025-3-22 16:09 作者: GLARE 時間: 2025-3-22 18:41
,Theorie ergodique de l’equirepartition,ys and next-generation sequencing technologies, have identified a number of recurrent lesions that can be grouped into several targetable pathways, including Notch, Jak/Stat, MAPK/Ras, PI3K/Akt/mTOR, and cyclin-dependent kinase signaling. Other newer methods to target T-ALL include the use of epigen作者: Banquet 時間: 2025-3-22 21:20
,Theorie ergodique de l’equirepartition,icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire作者: 不要不誠實 時間: 2025-3-23 04:34
Molecular Pathways and Targets in B-Cell Progenitor Acute Lymphoblastic Leukemiag germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos作者: Aggrandize 時間: 2025-3-23 06:39 作者: 捐助 時間: 2025-3-23 09:57 作者: 填料 時間: 2025-3-23 17:46
Treatment of Ph-Like Acute Lymphoblastic Leukemia Ph-like ALL across the age spectrum has subsequently led to current precision medicine trials investigating the therapeutic potential of tyrosine kinase inhibitor-based therapies for children, adolescents, and adults with Ph-like ALL. These efforts have been somewhat challenging to translate given 作者: Facet-Joints 時間: 2025-3-23 20:01
Prophylaxis and Treatment of Central Nervous System (CNS) Acute Lymphoblastic Leukemiaotherapy. Despite great advancements, the CNS remains the most common site of extramedullary relapse, and treatment of CNS relapse remains clinically challenging in patients with ALL. This chapter will review current methods of diagnosing and treating CNS leukemia and evaluating risk of CNS relapse,作者: Thyroid-Gland 時間: 2025-3-23 23:15 作者: 都相信我的話 時間: 2025-3-24 03:48
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire作者: legitimate 時間: 2025-3-24 08:56
Clinical Management of Acute Lymphoblastic LeukemiaFrom Bench to Bedsid作者: genuine 時間: 2025-3-24 13:44
Clinical Management of Acute Lymphoblastic Leukemia978-3-030-85147-7作者: 我說不重要 時間: 2025-3-24 17:05 作者: 剝削 時間: 2025-3-24 20:06
Pierre-André Cornillon,Eric Matzner-L?berted agents for R/R disease is already having a positive impact. These approaches are currently being investigated in the frontline setting, bringing promise for continued outcome improvements, ideally with fewer adverse short- and long-term treatment effects.作者: MERIT 時間: 2025-3-25 00:52
B. Bauer,A. Bouchard,P. Tripon,S. Rigalccess of highly effective therapies also to older and less fit patients. The possibility of devising largely chemotherapy-free regimens and avoiding allogeneic HSCT in an increasing proportion of patients is becoming a credible concept and marks a paradigm change for treatment of acute leukemias.作者: 有斑點 時間: 2025-3-25 03:44 作者: 污點 時間: 2025-3-25 07:35
https://doi.org/10.1007/BFb0074253t in determining who may derive the most benefit from HSCT, as well as the optimal timing of such an intervention. Meanwhile, advances in the development of alternative donor sources and reduced-intensity conditioning regimens have expanded its potential application.作者: HAVOC 時間: 2025-3-25 11:56 作者: Malleable 時間: 2025-3-25 16:40 作者: Horizon 時間: 2025-3-25 21:14
Late Effects of Therapy of Acute Lymphoblastic Leukemiaon capture and reporting of even the most severe late effects, thus hampering meaningful comparisons of these across contemporary ALL protocols. This chapter summarizes the most prevalent late effects among ALL survivors and recent advances in mapping of these and outlines strategies for future research.作者: graphy 時間: 2025-3-26 00:58 作者: FIR 時間: 2025-3-26 08:02 作者: 揉雜 時間: 2025-3-26 11:51 作者: 遣返回國 時間: 2025-3-26 13:07 作者: Insul島 時間: 2025-3-26 20:49
Genetic Mechanisms in T-Cell Acute Lymphoblastic LeukemiaMAPK, and PI3K signaling. In addition, aberrant expression of oncogenic transcription factors such as TAL1, LMO2, TLX1, and TLX3 and mutations in transcription factor tumor suppressors and epigenetic regulators result in altered differentiation and increased self-renewal.作者: 欲望 時間: 2025-3-26 21:32 作者: Foam-Cells 時間: 2025-3-27 01:39
,Régression sur variables qualitatives,MAPK, and PI3K signaling. In addition, aberrant expression of oncogenic transcription factors such as TAL1, LMO2, TLX1, and TLX3 and mutations in transcription factor tumor suppressors and epigenetic regulators result in altered differentiation and increased self-renewal.作者: 盡忠 時間: 2025-3-27 08:10 作者: Asperity 時間: 2025-3-27 13:03
Book 2022 behind ALL, reviewing molecular pathways and targets in B- and T-cell ALL, as well as techniques and application of minimal residual disease testing. The second section spotlights ALL management strategies for patients across the spectrum, from infants to the elderly. The final section outlines cur作者: 完成才能戰(zhàn)勝 時間: 2025-3-27 15:01
https://doi.org/10.1007/978-2-287-39693-9nequivocal prognostic value of MRD in ALL, several outstanding issues need to be addressed, such as optimal methods of MRD detection and monitoring, timing for MRD assessment, and interlaboratory standardization and implementation, to further improve MRD-based risk stratification and intervention.作者: 無王時期, 時間: 2025-3-27 20:28 作者: nonplus 時間: 2025-3-27 23:18 作者: 1FAWN 時間: 2025-3-28 02:34
Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphobels and early phase studies. In this chapter, we discuss the unique biological features of ALL in infants, provide a historical overview of the clinical trials and outcomes for infants with ALL, and offer insight into the novel treatment approaches in development.作者: 按時間順序 時間: 2025-3-28 10:20 作者: 諂媚于性 時間: 2025-3-28 13:53 作者: ornithology 時間: 2025-3-28 15:26
Minimal Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Application Post-treatment MRD measured by sensitive methods, including multiparametric flow cytometry and real-time quantitative polymerase chain reaction (RQ-PCR), has been incorporated into clinical risk assignment, resulting in substantially improved outcomes. In addition, a novel molecular method, high-th作者: JADED 時間: 2025-3-28 22:48 作者: jocular 時間: 2025-3-28 22:59
Treatment of Adult B- and T-Cell Acute Lymphoblastic Leukemia: An Overview of Current Treatments andet al., J Clin Oncol, 2012). Conversely, ALL is a challenging disease to treat in adults and has a modest prognosis (Jabbour et al., Cancer, 2015). The treatment paradigm for adult ALL adapted from pediatric regimens comprises combination chemotherapy with cycles of induction, consolidation, mainten作者: d-limonene 時間: 2025-3-29 03:50
Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphobgene (.-r) on chromosome band 11q23 is a defining cytogenetic feature that occurs in approximately 80% of infants with ALL and is associated with poor prognosis for long-term remission and survival. Infant ALL with .-r is characteristically poorly responsive to chemotherapy and hematopoietic stem ce作者: 做作 時間: 2025-3-29 10:33
Treatment of Elderly Patients with Acute Lymphoblastic Leukemia In sharp contrast, intensive pediatric chemotherapy regimens for children and adolescents/young adults (AYAs) achieve long-term disease-free remission rates of 80–90% and 50–70%, respectively. The poor prognosis of older adults with ALL is due to a high incidence of poor prognostic chromosomal and 作者: 同時發(fā)生 時間: 2025-3-29 12:56
Treatment of Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia been associated with poor outcome. The introduction of tyrosine kinase inhibitors targeting the BCR-ABL1 fusion protein to multiagent chemotherapy regimens has transformed the standard-of-care treatment approach for pediatric patients with Ph+?ALL, resulting in fewer patients being allocated to all作者: Biguanides 時間: 2025-3-29 19:03
Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia were confronted with a dismal prognosis, they can now expect an outcome similar – or even superior – to other subtypes of ALL. Importantly, these improvements in survival were brought about by an integrated approach in which introduction of TKI early in the therapeutic regimen was complemented by d作者: 影響帶來 時間: 2025-3-29 21:59
Treatment of Ph-Like Acute Lymphoblastic Leukemiaith high relapse risk and inferior clinical outcomes. Ph-like ALL was first recognized as having a kinase-activated gene expression profile (GEP) similar to that of Philadelphia chromosome-positive ALL (Ph+ ALL) and frequent . (.) alterations, yet lacking the canonical . oncogene fusion. Advances in作者: 圓木可阻礙 時間: 2025-3-30 02:59
Prophylaxis and Treatment of Central Nervous System (CNS) Acute Lymphoblastic Leukemiart to the discovery of the central nervous system (CNS) as a sanctuary site for leukemic blasts and implementation of CNS-directed therapy. With the application of risk-stratified, effective, systemic chemotherapy and prophylactic or treatment dosed CNS-directed interventions including intrathecal c作者: 行為 時間: 2025-3-30 05:32 作者: QUAIL 時間: 2025-3-30 09:47 作者: Cytokines 時間: 2025-3-30 15:43
New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemiagher frequency of induction failure and early relapse compared to B-cell acute lymphoblastic leukemia (B-ALL). Although treated with similar regimens, T-ALL is biologically distinct from B-ALL and shows a different kinetic pattern of disease response. While minimal residual disease (MRD) response re作者: Calculus 時間: 2025-3-30 17:00
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)t, tisagenlecleucel, for the treatment of relapsed and refractory B-ALL. Despite this success, several limitations of current CAR T cell products preclude the reliable use of this therapy as a durable curative treatment. Challenges in CAR T cell product manufacture, leukemia resistance to targeted t作者: 瘋狂 時間: 2025-3-30 21:26 作者: Truculent 時間: 2025-3-31 01:49 作者: Interim 時間: 2025-3-31 05:39 作者: Rejuvenate 時間: 2025-3-31 12:26
,La régression linéaire multiple,basis of B-progenitor ALL. These studies have identified multiple new subtypes of B-ALL and have shown that many of these new subtypes are driven by diverse genetic alterations in addition to those previously characterized by aneuploidy or a single fusion oncoprotein. These include subtypes driven b作者: 軍械庫 時間: 2025-3-31 16:46
,Régression sur variables qualitatives,l growth, proliferation, and survival disruption in early T-cell progenitors and disrupt transcriptional programs that control early thymocyte development. Highly prevalent genetic lesions induce constitutive activation of NOTCH1 signaling, deregulated cell cycle progression, and aberrant JAK-STAT,
